Pharming Group (NASDAQ:PHAR) Short Interest Update

Pharming Group (NASDAQ:PHARGet Free Report) saw a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 300 shares, a drop of 72.7% from the January 31st total of 1,100 shares. Based on an average daily volume of 1,900 shares, the days-to-cover ratio is currently 0.2 days.

Pharming Group Price Performance

Shares of PHAR stock traded down $0.06 during mid-day trading on Wednesday, hitting $11.10. 2,181 shares of the stock traded hands, compared to its average volume of 2,255. Pharming Group has a twelve month low of $9.65 and a twelve month high of $17.81. The firm has a market cap of $744.92 million, a price-to-earnings ratio of -35.81 and a beta of 0.22. The company’s 50-day simple moving average is $11.96 and its 200-day simple moving average is $11.94. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.50 and a current ratio of 4.29.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. Silverberg Bernstein Capital Management LLC bought a new position in Pharming Group (NASDAQ:PHARFree Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 17,710 shares of the company’s stock, valued at approximately $202,000. Hedge funds and other institutional investors own 0.04% of the company’s stock.

Pharming Group Company Profile

(Get Free Report)

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.

Read More

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.